Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 9/20 | 0.43 |
| ▸ | DRD4 | P21917 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234969 | 0.96 | MEN1 (0.50) | MEN1KMT2ACACNA1GHTR7KCNH2 | |
| SCHEMBL4248320 | 0.87 | CACNA1G (0.59) | CACNA1GHTR7DRD2DRD4HTR2A | |
| SCHEMBL3224887 | 0.86 | SIGMAR1 (0.54) | HTR7KCNH2DRD2DRD4DRD3 | |
| SCHEMBL3219699 | 0.86 | CNR1 (0.53) | MEN1KMT2ACACNA1GHTR7KCNH2 | |
| SCHEMBL3231847 | 0.86 | MEN1 (0.53) | MEN1KMT2ACACNA1GKCNH2DRD2 | |
| SCHEMBL3233134 | 0.85 | MEN1 (0.49) | MEN1KMT2ACACNA1GHTR7KCNH2 | |
| SCHEMBL3234351 | 0.84 | CACNA1G (0.47) | CACNA1GHTR7DRD2DRD4SMN1; SMN2 | |
| SCHEMBL3225148 | 0.84 | CACNA1G (0.49) | MEN1KMT2ACACNA1GHTR7KCNH2 | |
| SCHEMBL3234760 | 0.83 | MEN1 (0.43) | MEN1KMT2ACACNA1GHTR7DRD2 | |
| SCHEMBL3219753 | 0.82 | MEN1 (0.53) | MEN1KMT2ACACNA1GDRD2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236806-B2 | Piperazinyl-propyl-pyrazole derivatives as dopamine D4 receptor antagonists, and pharmaceutical compositions containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-08-07 | — | — | US | claimed |
| US-20100063286-A1 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-11 | — | — | US | claimed |
| US-8372844-B2 | Piperazinyl-propyl-pyrazole derivatives as dopamine D4 receptor antagonists, and pharmaceutical compositions containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-02-12 | — | — | US | disclosed |
| US-20120209001-A1 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-08-16 | — | — | US | disclosed |
| US-8236806-B2 | Piperazinyl-propyl-pyrazole derivatives as dopamine D4 receptor antagonists, and pharmaceutical compositions containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-08-07 | — | — | US | disclosed |
| US-20100063286-A1 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-11 | — | — | US | disclosed |
| WO-2008108517-A2 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120209001-A1 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | HTR3B, HTR3C, HTR3D | MEN1 3749/4885KMT2A 4390/4885CACNA1G 2726/4885 |
| US-20100063286-A1 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | HTR3B, HTR3C, HTR3D | MEN1 3749/4885KMT2A 4390/4885CACNA1G 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.